CoChat

Genomic landscape of high-grade meningiomas

Open access
Bi, Wenya Linda, Greenwald, Noah F., Abedalthagafi, Malak, Wala, Jeremiah, Gibson, Will J., Agarwalla, Pankaj K., Horowitz, Peleg, Schumacher, Steven E., Esaulova, Ekaterina, Mei, Yu, Chevalier, Aaron, A. Ducar, Matthew, Thorner, Aaron R., van Hummelen, Paul, O. Stemmer-Rachamimov, Anat, Artyomov, Maksym, Al-Mefty, Ossama, Dunn, Gavin P., Santagata, Sandro, Dunn, Ian F., Beroukhim, Rameen · 2017 · npj Genomic Medicine
Cited by 210

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

High-grade meningiomas frequently recur and are associated with high rates of morbidity and mortality. To determine the factors that promote the development and evolution of these tumors, we analyzed the genomes of 134 high-grade meningiomas and compared this information with data from 595 previously published meningiomas. High-grade meningiomas had a higher mutation burden than low-grade meningiomas but did not harbor any significantly mutated genes aside from NF2. High-grade meningiomas also possessed significantly elevated rates of chromosomal gains and losses, especially among tumors with monosomy 22. Meningiomas previously treated with adjuvant radiation had significantly more copy number alterations than radiation-induced or radiation-naïve meningiomas. Across serial recurrences, genomic disruption preceded the emergence of nearly all mutations, remained largely uniform across time, and when present in low-grade meningiomas correlated with subsequent progression to a higher grade. In contrast to the largely stable copy number alterations, mutations were strikingly heterogeneous across tumor recurrences, likely due to extensive geographic heterogeneity in the primary tumor. While high-grade meningiomas harbored significantly fewer overtly targetable alterations than low-grade meningiomas, they contained numerous mutations that are predicted to be neoantigens, suggesting that immunologic targeting may be of therapeutic value.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41525-017-0014-7

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 210

Metadata

Authors
Bi, W. L., Greenwald, N. F., Abedalthagafi, M., Wala, J., Gibson, W. J., Agarwalla, P. K., Horowitz, P., Schumacher, S. E., Esaulova, E., Mei, Y., Chevalier, A., A. Ducar, M., Thorner, A. R., van Hummelen, P., O. Stemmer-Rachamimov, A., Artyomov, M., Al-Mefty, O., Dunn, G. P., Santagata, S., Dunn, I. F., & Beroukhim, R.
Venue
npj Genomic Medicine
Published
2017-04-26
Volume
2
Issue
1
ISSN
2056-7944 (ISSN-L)
OpenAlex
W2606807227
Cited by
210
References
11
FWCI
10.94
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genomic landscape of high-grade meningiomas. https://app.cochat.ai/papers/10.1038/s41525-017-0014-7
The paper
Bi, W. L., Greenwald, N. F., Abedalthagafi, M., Wala, J., Gibson, W. J., Agarwalla, P. K., Horowitz, P., Schumacher, S. E., Esaulova, E., Mei, Y., Chevalier, A., A. Ducar, M., Thorner, A. R., van Hummelen, P., O. Stemmer-Rachamimov, A., Artyomov, M., Al-Mefty, O., Dunn, G. P., Santagata, S., . . . Beroukhim, R. (2017). Genomic landscape of high-grade meningiomas. npj Genomic Medicine. https://doi.org/10.1038/s41525-017-0014-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.